Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX ...

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company ...

Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ ... The shares are primarily held through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where Walmsley is a managing ...

Shares of AKRO stock opened at $45.54 on Monday. The stock’s 50-day moving average is $39.27 and its 200 day moving average is $32.78. Akero Therapeutics has a 1-year low of $17.86 and a 1-year ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC.